We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+26.87%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$494M
AUM Growth
+$67.8M
(+16%)
Cap. Flow
-$71M
Cap. Flow
% of AUM
-14.37%
Top 10 Holdings %
Top 10 Hldgs %
52.79%
Holding
80
New
31
Increased
8
Reduced
10
Closed
27
Top Buys
| 1 |
Sarepta Therapeutics
SRPT
|
+$15.7M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$15.1M |
| 3 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
+$12.1M |
| 4 |
FOLD
Amicus Therapeutics
FOLD
|
+$11.4M |
| 5 |
Gyre Therapeutics
GYRE
|
+$11.2M |
Top Sells
| 1 |
ESPR
Esperion Therapeutics
ESPR
|
+$15.1M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$13.8M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$12.8M |
| 4 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$11M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$9.37M |
Sector Composition
| 1 | Healthcare | 63.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
Incyte
INCY
$23.4B
| $83.3M | 16.86% |
+8,333
| New | +$751K |
|
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $35.1M | 7.1% |
8,773
-841,227
| -99% | -$76.8M |
|
|
IMMU
3
DELISTED
Immunomedics Inc
IMMU
| $27M | 5.47% |
1,850,000
+312,000
| +20% | +$5.1M |
|
|
ECYT
4
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $20M | 4.05% |
+2,200,000
| New | +$12.1M |
|
|
5
Sarepta Therapeutics
SRPT
$1.82B
| $17.4M | 3.52% |
+235,000
| New | +$15.7M |
|
|
6
Iovance Biotherapeutics
IOVA
$2.23B
| $16.9M | 3.42% |
+1,000,000
| New | +$15.1M |
|
|
AVXS
7
DELISTED
AveXis, Inc. Common Stock
AVXS
| $16.7M | 3.38% |
135,000
+50,000
| +59% | +$5.94M |
|
8
Rocket Pharmaceuticals
RCKT
$376M
| $15.9M | 3.22% |
850,000
+525,000
| +162% | +$8.56M |
|
9
Viatris
VTRS
$20.1B
| $14.4M | 2.92% |
350,000
+100,000
| +40% | +$4.26M |
|
|
BHVN
10
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $14.2M | 2.87% |
550,000
+365,000
| +197% | +$10.9M |
|
11
argenx
ARGX
$53.8B
| $12.1M | 2.44% |
150,000
-100,000
| -40% | -$7.55M |
|
|
12
Gyre Therapeutics
GYRE
$675M
| $11.6M | 2.35% |
+60,000
| New | +$11.2M |
|
|
FOLD
13
DELISTED
Amicus Therapeutics
FOLD
| $11.3M | 2.28% |
+750,000
| New | +$11.4M |
|
|
BPMC
14
DELISTED
Blueprint Medicines
BPMC
| $11M | 2.23% |
120,000
-30,000
| -20% | -$2.59M |
|
15
Ascendis Pharma A/S
ASND
$17.1B
| $9.16M | 1.85% |
140,000
-110,000
| -44% | -$6.18M |
|
|
DRNA
16
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $9.08M | 1.84% |
950,000
+450,000
| +90% | +$4.85M |
|
|
MNTA
17
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $9.07M | 1.84% |
+500,000
| New | +$8.34M |
|
18
Acadia Pharmaceuticals
ACAD
$4.38B
| $8.99M | 1.82% |
+400,000
| New | +$11.1M |
|
|
MRTX
19
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.06M | 1.63% |
262,500
-337,500
| -56% | -$9.37M |
|
|
CNCE
20
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $8.02M | 1.62% |
+350,000
| New | +$7.78M |
|
|
ADMS
21
DELISTED
Adamas Pharmaceuticals
ADMS
| $7.77M | 1.57% |
+325,000
| New | +$10.2M |
|
|
AGN
22
DELISTED
Allergan plc
AGN
| $7.57M | 1.53% |
45,000
-750
| -2% | -$126K |
|
23
Assembly Biosciences
ASMB
$531M
| $7.37M | 1.49% |
+12,500
| New | +$7.75M |
|
24
Travere Therapeutics
TVTX
$5.27B
| $7.03M | 1.42% |
+314,367
| New | +$7.49M |
|
|
KDMN
25
DELISTED
Kadmon Holdings, Inc.
KDMN
| $6.8M | 1.38% |
1,600,000
+900,000
| +129% | +$3.85M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q1 2018 Portfolio in Review
As of Q1 2018, Ghost Tree Capital held 80 positions worth $494M, up 16% from $426M the previous quarter. Its ten largest holdings account for 53% of the portfolio.
Ghost Tree Capital withdrew a net $71M in Q1 2018, closing 27 positions and reducing 10 holdings. Its most notable exit was Esperion Therapeutics, an estimated $15.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 52% a quarter earlier.
Against the trend, Ghost Tree Capital opened a new position in Sarepta Therapeutics worth $17.4M.
- Ghost Tree Capital's largest Q1 2018 buy was Sarepta Therapeutics: 235,000 shares worth $17.4M.
- Ghost Tree Capital added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018, an estimated $10.9M increase.
- Ghost Tree Capital's biggest Q1 2018 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $9.37M.
- Ghost Tree Capital fully exited Esperion Therapeutics in Q1 2018, selling an estimated $15.1M.
- Ghost Tree Capital's ten largest holdings make up 53% of its $494M portfolio in Q1 2018.
- Ghost Tree Capital opened 31 new positions and closed 27 in Q1 2018.
- Ghost Tree Capital's portfolio value rose 16% quarter-over-quarter to $494M.
Based on Ghost Tree Capital's 13F filing for Q1 2018, filed 15 May 2018.